- Home
- ENTA vs STRW Comparison
ENTA vs STRW Comparison
Compare ENTA & STRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- STRW
- Stock Information
- Founded
- ENTA 1995
- STRW 2015
- Country
- ENTA United States
- STRW United States
- Employees
- ENTA N/A
- STRW N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- STRW Real Estate Investment Trusts
- Sector
- ENTA Health Care
- STRW Real Estate
- Exchange
- ENTA Nasdaq
- STRW Nasdaq
- Market Cap
- ENTA 154.0M
- STRW 133.6M
- IPO Year
- ENTA 2013
- STRW N/A
- Fundamental
- Price
- ENTA $5.27
- STRW $10.15
- Analyst Decision
- ENTA Buy
- STRW Strong Buy
- Analyst Count
- ENTA 4
- STRW 4
- Target Price
- ENTA $17.25
- STRW $13.83
- AVG Volume (30 Days)
- ENTA 194.0K
- STRW 45.5K
- Earning Date
- ENTA 05-20-2025
- STRW 05-09-2025
- Dividend Yield
- ENTA N/A
- STRW 5.47%
- EPS Growth
- ENTA N/A
- STRW 34.22
- EPS
- ENTA N/A
- STRW 0.58
- Revenue
- ENTA $66,590,999.00
- STRW $126,557,000.00
- Revenue This Year
- ENTA N/A
- STRW $15.21
- Revenue Next Year
- ENTA N/A
- STRW $2.21
- P/E Ratio
- ENTA N/A
- STRW $17.34
- Revenue Growth
- ENTA N/A
- STRW 22.41
- 52 Week Low
- ENTA $4.09
- STRW $8.70
- 52 Week High
- ENTA $17.24
- STRW $12.90
- Technical
- Relative Strength Index (RSI)
- ENTA 45.38
- STRW 41.28
- Support Level
- ENTA $4.96
- STRW $10.00
- Resistance Level
- ENTA $6.23
- STRW $11.50
- Average True Range (ATR)
- ENTA 0.33
- STRW 0.68
- MACD
- ENTA -0.01
- STRW -0.06
- Stochastic Oscillator
- ENTA 24.41
- STRW 15.09
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.